Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem (FACILITATE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Italy,Austria,Germany,Germany,Spain,Italy,Italy,Italy,Belgium,Finland,Poland,Switzerland,Switzerland,Sweden,Romania,Serbia,Serbia,France,France,France,France,Czechia,Netherlands,United States,United Kingdom,United Kingdom
Call: Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework (H2020-JTI-IMI2-2020-23-two-stage, 2020)
Start date: 2022-01-01
End date: 2025-12-31
Duration (months): 48.0
Total project cost (EUR): 6886711.0
EU funding (EUR): 3260000.0
Participants: 29
Project status: SIGNED

FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process allows the returning of clinical trial data to study participants within a GDPR compliant and approved ethical framework. FACILITATE starts-off by providing clear rules in a trusted ethical, legal and regulatory ecosystem before engaging patients as data generators. This avoids the current situation where clinical data are siloed in separate repositories without any possibility to be used beyond their original single-sided purpose. FACILITATE will provide the technological solutions to comply with GDPR in medical research by building on the empowered stakeholders' willingness to share and re-use their data. The FACILITATE Consortium was constituted by drawing from a broad range of capacities to tackle the ambitious challenges related to future clinical trials, such as preventive, long-term and real-world evidence trials. The Consortium took an innovative approach to the data return to study participants by asking them what they needed to be implemented to feel in a trusted ecosystem. This required all Consortium participants to leverage on their existing networks to bring together stakeholders at all levels in the decision-making chain, including patients, healthcare professionals, software designers, clinical trials repositories processors and controllers, ethicists, lawyers and other active regulators. Having obtained a consent on the data portability FACILITATE will re-use and cross-reference them with those contained in other repositories including RWE data captured across multiple settings and devices. FACILITATE will last 4 years and will participate in the extended Pilot on Open Research Data of Horizon 2020. Its strategy represents a unique and innovative opportunity for medicines drug development and regulation to better understand the clinics of diseases, and to evaluate the effectiveness of products in the healthcare system.

Keywords: gdpr,patient centred,big data,clinical trials,ethical,legal and regulatory framework
REGENERATING NATURAL AESTHETICS (REGENERA)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Italy
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-08-01
End date: 2017-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Every Year, globally ca. 0.8 million people experience reconstructive surgery after mastectomy or lumpectomy and 1.2 million undergo breast augmentation surgery. Currently, breast defects are not properly reconstructed but only temporary filled with silicone implants, which however present several drawbacks such as the need of substitution after approximately 10 years, rupture (30% of incidence), leakage and capsular contracture. An alternative procedure that is currently available in clinics is fat autotransplantation. However, this technique presents potential carcinogenic risks and is still limited to small volumes, requiring multiple interventions to achieve larger reconstructions. REGENERA is an innovative mammary prosthesis based on biodegradable, porous, synthetic biomaterials and manufactured with internal micro-channels replicating the blood-vessels architecture. This distinctive combination, obtained by a patented process, promotes the natural fat growth, and allows the regeneration of a large adipose tissue volume. REGENERA’s overall objective is to improve patients’ quality of life, by restoring permanently the breast’s natural shape, appearance and size following a mastectomy/lumpectomy. Moreover, since REGENERA does not require further surgical operations for the rest of the patient’s life, it can drastically reduce the pain of the patient and decrease the associated Healthcare costs. REGENERA specific objective is to provide a biocompatible support able to induce the ingrowth of adipocytes and subsequently degrade, allowing the complete maturation of a stable adipose tissue, that replaces the original volume occupied by the prosthesis.

Keywords: breast reconstruction,adipose tissue
Bioengineering lung tissue using extracellular matrix based 3D bioprinting (3DBIOLUNG)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Sweden
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-01-01
End date: 2023-12-31
Duration (months): 60.0
Total project cost (EUR): 1499975.0
EU funding (EUR): 1499975.0
Participants: 1
Project status: SIGNED

Chronic lung diseases are increasing in prevalence with over 65 million patients worldwide. Lung transplantation remains the only potential option at end-stage disease. Around 4000 patients receive lung transplants annually with more awaiting transplantation, including 1000 patients in Europe. New options to increase available tissue for lung transplantation are desperately needed. An exciting new research area focuses on generating lung tissue ex vivo using bioengineering approaches. Scaffolds can be generated from synthetic or biologically-derived (acellular) materials, seeded with cells and grown in a bioreactor prior to transplantation. Ideally, scaffolds would be seeded with cells derived from the transplant recipient, thus obviating the need for long-term immunosuppression. However, functional regeneration has yet to be achieved. New advances in 3D printing and 3D bioprinting (when cells are printed) indicate that this once thought of science-fiction concept might finally be mature enough for complex tissues, including lung. 3D bioprinting addresses a number of concerns identified in previous approaches, such as a) patient heterogeneity in acellular human scaffolds, b) anatomical differences in xenogeneic sources, c) lack of biological cues on synthetic materials and d) difficulty in manufacturing the complex lung architecture. 3D bioprinting could be a reproducible, scalable, and controllable approach for generating functional lung tissue. The aim of this proposal is to use custom 3D bioprinters to generate constructs mimicking lung tissue using an innovative approach combining primary cells, the engineering reproducibility of synthetic materials, and the biologically conductive properties of acellular lung (hybrid). We will 3D bioprint hybrid murine and human lung tissue models and test gas exchange, angiogenesis and in vivo immune responses. This proposal will be a critical first step in demonstrating feasibility of 3D bioprinting lung tissue.

Keywords: lung tissue engineering,lung bioengineering,ex vivo lung regeneration,3d bioprinting
Sampling Protein cOmplex Conformational Space with native top down Mass Spectrometry (SPOCkS MS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Molecules of Life: Biological Mechanisms, Structures and Functions
Panel description: Molecular biology, biochemistry, structural biology, molecular biophysics, synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: Germany
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-01-01
End date: 2024-09-30
Duration (months): 81.0
Total project cost (EUR): 1999000.0
EU funding (EUR): 1999000.0
Participants: 1
Project status: SIGNED

The main question to be addressed by SPOCk’S MS is how protein complex conformation adapts to local changes, such as processing of polyproteins, protein phosphorylation or conversion of substrates. While labelling strategies combined with mass spectrometry (MS), such as hydrogen deuterium exchange and hydroxyl footprinting, are very versatile in studying protein structure, these techniques are employed on bulk samples averaging over all species present. SPOCk’S MS will remedy these by studying the footprinting and therefore exposed surface area on conformation and mass selected species. Labelling still happens in solution avoiding gas phase associated artefacts. The labelling positions are then read out using newly developed top-down MS technology. Ultra-violet and free-electron lasers will be employed to fragment the protein complexes in the gas phase. In order to achieve the highest possible sequence and thus structural coverage, lasers will be complemented by additional dissociation and separation stages to allow MS^N. SPOCk’S MS will allow sampling conformational space of proteins and protein complexes and especially report about the transient nature of protein interfaces. Constraints derived in MS will be fed into a dedicated software pipeline to derive atomistic models. SPOCk’S MS will be used to study intracellular viral protein complexes, especially coronaviral replication/transcription complexes, which are highly flexible and often resist crystallisation and are barely accessible by conventional structural biology techniques. Objectives: - Integrate labelling with complex species selective native MS for time-resolved structural studies - Combine fragmentation techniques to maximise information content from MS - Develop software suite to analyse data and model protein complex structures based on MS constraints - Apply SPOCk’S MS to protein complexes of human pathogenic viruses

Keywords: mass spectrometry,fragmentation techniques,labelling,structural proteomics,structural and biophysical virology,free electron lasers
Development of a commercial manufacturing process for a low cost, small footprint, high efficiency fully electric compressor and power controls to fulfil a market need for use in heavy goods vehicles (HiPower)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: United Kingdom
Call: Small business innovation research for Transport (H2020-SMEINST-1-2015, 2015)
Start date: 2016-04-01
End date: 2016-06-30
Duration (months): 3.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Equipmake Ltd have a deep history of developing innovative technologies for niche and specialist markets such as Formula 1. Increasing demand for electrification in the commercial vehicles (CV) sector has created a new market for our electric traction motor and ultra high speed motor to create a highly efficient electric compressor for the CV sector. New legislations are creating an acute need and market pull amongst CV manufacturers for innovative solutions to meet new emission targets. The need is most acute amongst Heavy Goods/Commercial Vehicle (HGV/HCV) manufacturers. From this September, all new cars and light vans must abide by the new Euro6 regulations, and will be enforced for all HGVs by 2018. Over the past 23 years, the Nitrous Oxide (NOx) and Particulate Matter (PM) levels have been targeted with an overall 99% reduction. NOx is highly dangerous and linked to premature deaths and other health complications. The new standard requires a 55% drop in NOx from Euro5 of 180mg/km. This is bringing an increased need for electrification in the transport sector , creating a need for cost effective electric and hybrid technology for vehicles. HiPower will address this market opportunity with tests showing that we have a 66% smaller, 66% lighter compressor which is 50% cheaper, bringing both weight and cost savings to end users with a 22% increase in efficiency compared to nearest competing solutions. Calculations show that HiPower will create savings of 9,413 kg CO2 HGV/annum in conventional diesel engines and 1,552 kG CO2/bus/annum on electric buses in addition to the €5.9k saving on battery cost over normal compressors. We will create market entry using low hanging fruit of the electric bus market to then penetrate the high volume HGV market. 5-year gross profits of €101m from €103m revenues will include royalty fees on high volume manufacture, generating a 5-year ROI of 30:1.

Keywords: efficient,compressor,electric vehicle,high speed,electrification,lorry,truck,electric
Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies (NovAnI)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Synthetic Chemistry and Materials
Panel description: New materials and new synthetic approaches, structure-properties relations, solid state chemistry, molecular architecture, organic chemistry
Countries involved: Germany
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-02-01
End date: 2023-01-31
Duration (months): 60.0
Total project cost (EUR): 1499367.0
EU funding (EUR): 1499367.0
Participants: 1
Project status: CLOSED

Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed. I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known: 1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development. I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives. This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Keywords: medicinal chemistry,hit identification,anti infectives
Analysis of the oxidative modifications on casein micelles exposed to different oxidative sources: determining the impact of these modifications at a structural and nutritional level (CASMOX)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-08-01
End date: 2022-07-31
Duration (months): 24.0
Total project cost (EUR): 207312.0
EU funding (EUR): 207312.0
Participants: 1
Project status: CLOSED

Oxidative damage is a major problem for dairy industry as it can occur to a significant extent during the processing and/or storage of milk, and results in significant wastage. Due the high abundance of proteins, ~30% of the dry mass of whole milk, these represent one of the most abundant targets of damage. Protein oxidation can have a direct impact on the nutritional value of milk and the consumption of highly oxidised proteins may have deleterious consequences for human health. This project will provide an improved understanding of the degradation pathways of the most abundant milk proteins (caseins), the micelle structures that these proteins form, and the key drivers of these reactions. To address these aims, this project will: (1) investigate the oxidation of casein micelle (CM) mediated by the most relevant oxidative sources generated during milk processing and storage, and (2) determine the consequences of CM oxidation on their nutritional value (i.e. loss of parent amino acids) and the biological effects (i.e. decreased digestibility, toxicity to human cells). The approaches to be used in this project include analytical, biochemical and biological techniques (i.e. liquid chromatography, SDS-PAGE, western blotting, mass spectrometry, electron microscopy, cell culture models). The project is of interest to the European community as milk and dairy products represent one of the most consumed food materials, with health and nutrition claims for these products based on the presence of specific materials, such as proteins. It is therefore critically important that these claims are justified and correct. This project will provide important new knowledge, as there are currently no data available as to the pathways responsible for CM oxidative modifications. Such data is a pre-requisite to the development of lessharmful industrial milk processing methods. The project will also validate new methods to examine the nutritional quality of milk and dairy products.

Keywords: casein micelle,protein oxidation,aggregation,peroxyl radicals,riboflavin,hydroperoxides,health,nutrition
Ultra-Dense Unsupervised Heterogeneous Wireless Cloud Coded Networks for 5G/B5G (RECENT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Türkiye,Finland,United Kingdom,Portugal
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2018, 2018)
Start date: 2018-11-01
End date: 2023-10-31
Duration (months): 60.0
Total project cost (EUR): 897000.0
EU funding (EUR): 897000.0
Participants: 4
Project status: SIGNED

Beyond 5G (B5G) wireless networks will undoubtedly have greatly increased density and scale compared to current networks, resulting in massive interaction between nodes. It will be infeasible to provide fixed connections to all access nodes, and hence these networks will evolve towards a heterogeneous, multihop, self-organizing architecture. Moreover, for several significant B5G scenarios (such as vehicular networks in "smart cities") the topology may be a priori unknown and rapidly time-variant: therefore, it will be impractical to provide a global coordinating authority, and hence these networks will be essentially unsupervised. (Security remains paramount, and physical security mechanisms especially appropriate.) The conventional networking paradigm will be severely limited by interference in these scenarios, greatly reducing efficiency. It has already been shown in both theory and practice that wireless physical-layer network coding (WPNC) is nevertheless capable of resolving this situation because it can allow relay nodes to extract useful information from all combined received signals, rather than treating them as deleterious interference. However, previous work on WPNC [1-5] has not addressed the case of large-scale, unsupervised, secure, dynamic networks. RECENT will address such networks starting with fundamental theory and technology, including information theory, network coded modulation (NCM) for WPNC, stochastic network theory, and physical layer security. The developed technologies will be deployed and validated in the system level simulator and hardware-in-the-loop (HIL) platform. Running in parallel to the technical activities, a rigorously crafted innovation management programme will assess business opportunities of RECENT technologies, taking into consideration standards and regulation, and hence ensure that they achieve their full industrial and societal impact.

Keywords: hetnet,unsupervised networks,simulation modelling
“Innovation Dialogues Europe-Africa” D4D Hub (IDEA D4D HUB)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Coordination and support actions
Countries involved: Germany,Germany,Belgium,France,Rwanda
Call: International partnership building between European and African innovation hubs (H2020-ICT-2020-2, 2020)
Start date: 2021-12-01
End date: 2023-09-30
Duration (months): 22.0
Total project cost (EUR): 999700.0
EU funding (EUR): 999700.0
Participants: 5
Project status: SIGNED

IDEA D4D Hub is boosting inter-African and African-European multi-stakeholder dialogue and collaboration in the digital society by supporting and strengthening the role of ICT/digitalisation stakeholders, precisely civil society and academia, to engage and contribute actively to multi-stakeholder dialogues for human-centred digital transformation and by supporting the development of joint digital innovations as a response to societal challenges that hinder an inclusive digital society. The activities of the project are based on the recommendations of the EU-AU task force on the digital economy, in particular in the area of research and innovation and will support the implementation of the EU’s Digital4Development strategy, Common Research, Development and Innovation priorities, African Union Agenda 2063, Africa Connect and Africa-Europe Alliance for Sustainable Investment and Jobs.

Keywords: africa eu collaboration,digital economy and society,civil socitey